Arcturus Therapeutics Schedules Q4 and Fiscal Year 2025 Earnings Release for March 3

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, announced that it will release its financial results for the quarter and year ended December 31, 2025 after the market close on Tuesday, March 3 and will also host a conference call and webcast at 4:30 p.m. Eastern Time on March 3, 2026.

The earnings conference call will be accessible domestically at 1-800-274-8461 and internationally at 1-203-518-9814, with conference ID: ARCTURUS. A webcast will also be available.

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. is a commercial mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise.

Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration with CSL Seqirus, U.S. BARDA for pandemic flu and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics.

Arcturus' pipeline includes RNA therapeutic candidates to potentially treat cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA (siRNA), circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.

Arcturus' technologies are covered by its extensive patent portfolio (over 500 patents and patent applications in the U.S., Europe, Japan, China, and other countries).